Cannabis Inhaler Market - Global Market Share, Trends, Analysis and Forecast 2023 - 2032

The global cannabis inhaler market is expected to grow at a CAGR of 7.2% between 2023 and 2032.

Cannabis is legally banned in most countries due to its harmful effects, such as extreme addiction. However, in 36 US states, Cannabis is legalized for medicinal and recreational use under the government's set rules and regulations. Cannabis stevia or the cannabis plant contains cannabinoids, natural compounds found quickly in them. The demand for Cannabis inhalers is expected to rise shortly because apart from their side effects on a human’s health, they can help overcome respiratory conditions such as Asthma and COPD, given that it is used under supervision and is well-monitored.

Cannabis Inhaler Market Market Trends

The Cannabis inhaler market is expected to rise shortly because of the high bioavailability of cannabis and the legalization of cannabis in various countries. There is a rise in government initiatives to promote safe and controlled usage of cannabis inhalers; various research projects have been funded to discover more uses of cannabis that might help treat various diseases.

The COVID-19 outbreak was a significant setback to the cannabis inhaler industry as there was a supply of fake medicines, which took away people's confidence in the medical sector, subsequently affecting the cannabis inhalers market.

Factors impacting the growth of the cannabis inhaler market

The lack of awareness on the long-term safety of cannabis used for medicinal purposes can act as a barrier to the profit boundaries in the cannabis inhaler market. In contrast, the changing regulatory outlook and initiatives by the government can act as a boost to the cannabis inhaler market. Asthma is a significant lung disease and potentially hazardous; the asthma segment has generated colossal revenue during the forecast period and has dominated the market.

UK, Germany, and Cyprus have considered cannabis a prescription-based medicinal product, allowing only registered therapeutic practitioners to prescribe it to their patients. Countries such as Sweden, Latvia, Belgium, etc., have put a total ban on Cannabis. This shows the partial acceptance of cannabis inhalers in the European market.

Cannabis for medicinal and recreational purposes is legalized in 36 US states but is banned by federal law due to its residual side effects. The legalization of Cannabis on state levels is a significant boost to the increase in the Cannabis inhalers market in the United States of America.

Key market players

• CBD Luxe
• Fairwinds cannabis
• H and T presspart manufacturing LTD.
• Koi CBD
• MUV
• Vectura Group plc

Segmentation of the market

By Application

• Asthma segment
• Wheezing
• Tightness in chest
• Others

By Geography

• North America
  • United States
  • Canada
  • Rest of North America
• Europe
  • Germany
  • United Kingdom
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • India
  • China
  • Australia
  • Rest of Asia Pacific
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of the Middle East & Africa
• South America
  • Brazil
  • Rest of South America